Patent · US Active

Use of DPPIV/seprase as a marker for cancer

US10815517B2 · kind B2 · utility

0Cited by

1References

17Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Magdalena Swiatek-de Lange · Penzberg, DE
Johann Karl · Peißenberg, DE
Wolfgang Rollinger · Polling, DE

Key dates

Filing date	Oct 7, 2011
Grant date	Oct 27, 2020
Priority date	—
Expiry date	Oct 7, 2031

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/7028
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Described is a method aiding in the assessment of the presence of cancer. The method uses the soluble DPPIV/seprase protein complex (DPPIV/seprase) as a universal marker of different cancer types. Measurement of DPPIV/seprase complex can, e.g., be used in the early detection or diagnosis of cancer or in the surveillance of patients who undergo surgery.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.